Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial

BACKGROUND: Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of OPMD an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurizzan, Cristina, Lorini, Luigi, Paderno, Alberto, Tomasoni, Michele, Zigliani, Gabriele, Bozzola, Anna, Ardighieri, Laura, Battocchio, Simonetta, Bignotti, Eliana, Ravaggi, Antonella, Romani, Chiara, De Cecco, Loris, Serafini, Mara Serena, Miceli, Rosalba, Bardellini, Elena, Majorana, Alessandra, Piazza, Cesare, Bossi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130439/
https://www.ncbi.nlm.nih.gov/pubmed/34001010
http://dx.doi.org/10.1186/s12885-021-08297-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130439/
https://www.ncbi.nlm.nih.gov/pubmed/34001010
http://dx.doi.org/10.1186/s12885-021-08297-3

Ejemplares similares